Senju Pharmaceutical has patented a method for differentiating pluripotent stem cells into clinically applicable retinal ganglion cells. The process involves inducing differentiation through floating culture and promoting axon elongation via adhesion culture, which can also be used for screening substances for protective effects on retinal nerves. GlobalData’s report on Senju Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Senju Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Senju Pharmaceutical's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Method for differentiating stem cells into retinal ganglion cells
The granted patent US12024714B2 outlines a novel method for screening substances that may have protective or regenerative effects on retinal nerves. The method begins with the differentiation of pluripotent stem cells into retinal progenitor cells through a floating culture technique. Following this, the retinal progenitor cells are further differentiated into retinal ganglion cells, again utilizing floating culture conditions. Once the retinal ganglion cells are established, they undergo an adhesion culture process that allows for the elongation of their axons, which is a critical step in the development of functional nerve cells.
After the axons of the retinal ganglion cells have elongated, the method involves bringing a test substance into contact with these cells. The final step of the process is to evaluate the effects of the test substance on the retinal ganglion cells, specifically assessing any protective or regenerative outcomes. This systematic approach provides a framework for identifying potential therapeutic agents that could benefit conditions affecting retinal nerve health and function.
To know more about GlobalData’s detailed insights on Senju Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
